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Abstract: Methamphetamine (METH) use is associated with neurotoxic effects which include decreased levels of dopa-
mine (DA), serotonin (5-HT) and their metabolites in the brain. We have shown that escalating METH dosing can protect 
against METH induced neurotoxicity in rats sacrificed within 24 hours after a toxic METH challenge. The purpose of the 
current study was to investigate if the protective effects of METH persisted for a long period of time. We also tested if a 
second challenge with a toxic dose of METH would cause further damage to monoaminergic terminals. Saline-pretreated 
rats showed significant METH-induced decreases in striatal DA and 5-HT levels in rats sacrificed 2 weeks after the chal-
lenge. Rats that received two METH challenges showed no further decreases in striatal DA or 5-HT levels in comparison 
to the single METH challenge. In contrast, METH-pretreated rats showed significant protection against METH-induced 
striatal DA and 5-HT depletion. In addition, the METH challenge causes substantial decreases in cortical 5-HT levels 
which were not further potentiated by a second drug challenge. METH preconditioning provided almost complete protec-
tion against METH –induced 5-HT depletion. These results are consistent with the idea that METH pretreatment renders 
the brain refractory to METH-induced degeneration of brain monoaminergic systems.  
Keywords: Methamphetamine, striatum, dopamine, preconditioning. 
INTRODUCTION  
  Methamphetamine (METH) use is now a global epidemic 
because it has become easier to synthesize and administer  
[1, 2]. Chronic METH users suffer physiological harms,   
psychosis [3] and cognitive impairments [4]. METH also 
causes neurodegenerative changes in the brains of human 
addicts including decreases in the density of striatal dopa-
mine transporter (DAT) [5, 6] and serotonin transporter 
(SERT) [7] observed in positron emission tomography (PET) 
studies. Post-mortem studies have also provided evidence of 
marked decreases in striatal dopamine (DA) and DAT levels 
in METH abusers [8].  
  METH-induced neurodegenerative effects have been 
studied extensively using animal models. These abnormali-
ties include depletion of DA and its metabolites, 3,4-
dihyroxyphenylacetic acid (DOPAC) and homovallic acid 
(HVA) levels, DAT density in the striatum and nucleus   
accumbens [9], decreases in the levels of serotonin (5-HT) 
and its metabolite, 5-hydroxyindoleacetic acid (5-HIAA), 
SERT density [10] as well as cell death via activation of 
apoptotic pathways [11-13].  
  The vast majority of animal models investigating the 
biochemical effects of METH have utilized regimens in 
which either moderate to large doses of METH were injected 
several times within short intervals on a single day or   
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repeated exposure to high doses of METH over a period 
ranging from several days to several weeks [9, 14]. It has 
been suggested that these regimens might only model acute 
overdoses [9] because chronic METH users generally initiate 
drug use by taking small doses at variable intervals which 
they follow with gradual increases in the frequency and 
doses of METH intake [15, 16]. Animal models have indeed 
been developed in attempts to mimic those patterns of 
METH use and to evaluate the neurochemical effects of the 
drug on monoaminergic systems in the brain [17-21]. These 
models have shown that administration of repeated sub-toxic 
doses of METH can attenuate METH-induced damage in the 
striatum [17-19], nucleus accumbens [17], frontal cortex [17, 
18, 21] and hippocampus [20,  21].  
  We have recently published data documenting the effects 
of METH preconditioning on monoamine levels measured at 
24-hours after the toxic METH challenges [17, 19]. The pre-
sent study reports on the effects of METH pretreatment in 
animals killed 2 weeks after the last METH injections. In 
addition, we report on the neurochemical effects of two sepa-
rate drug challenges with toxic doses of METH. 
MATERIALS AND METHODS 
Animals 
  Male Sprague-Dawley rats (Charles River Laboratories, 
Raleigh NC) weighing approximately 350-400 g were ha-
bituated approximately one week prior to treatment. Animals 
were housed in polyethylene cages containing hardwood 
bedding in a humidity and temperature controlled room with 
a 12 hour light: dark cycle. Animals were given rat chow and 36    Current Neuropharmacology, 2011, Vol. 9, No. 1  Hodges et al. 
water ad libitum. All animals use procedures were performed 
according to the National Institutes of Health Guide for the 
Care and Use of Laboratory Animals and were approved by 
the local Animal Care Committee. 
Drug Treatment and Tissue Collection 
  Following habituation, each rat was injected i.p with pro-
gressively higher doses of METH-hydrocholoride (NIDA, 
Baltimore, MD) or an equivalent volume of saline as de-
scribed in Table 1. The saline-pretreated group was further 
divided into three subgroups. The first subgroup received 
saline on both challenge days (SSS). The second subgroup 
was challenged with METH (5 mg/kg X 6, given 1 hour 
apart) as previously described (SSM) [19]. The third sub-
group received two challenges of the same doses of METH 
with 2 intervening days (SMM) (see Table 1). The animals 
pre-treated with METH received METH on both challenge 
days (MMM). This approach generated 4 groups. Animals 
were weighed three times per week during the precondition-
ing period to ensure accurate dosing. Animals were also 
weighed on both challenge days as well as one and five days 
following the last challenge dose. Tympanic temperatures 
were taken thirty minutes prior to the first injection and 
thirty minutes after every other injection on the second   
challenge day. The animals were sacrificed 14 days follow-
ing the METH challenge by decapitation, their brains quickly 
removed and microdissected over ice, snap frozen on dry ice 
and stored at -80ºC until used in the HPLC analysis. 
HPLC Analysis 
  To quantify monoamine levels in each brain region, 
HPLC with electrochemical detection was used. Striatal, 
cortical and hippocampal samples (N=8 per group) were 
Table 1.  Schedule of METH Pre-Treatment and Challenges 
Week 1-Pretreatment 
    Monday Tuesday  Wednesday  Thursday Friday Saturday Sunday 
9:00  0.5 mg/kg  1.0 mg/kg  1.0 mg/kg  1.5 mg/kg          
10:00                      
11:00        1.0 mg/kg  1.5 mg/kg          
12:00                      
13:00        1.0 mg/kg  1.5 mg/kg          
14:00                      
15:00  0.5 mg/kg  1.0 mg/kg  1.0 mg/kg  1.5 mg/kg          
Week 2 - pretreatment 
9:00  1.0 mg/kg  1.5 mg/kg  2.0 mg/kg  2.5 mg/kg          
10:00                      
11:00  1.0 mg/kg  1.5 mg/kg  2.0 mg/kg  2.5 mg/kg          
12:00                      
13:00  1.0 mg/kg  1.5 mg/kg  2.0 mg/kg  2.5 mg/kg          
14:00                      
15:00  1.0 mg/kg  1.5 mg/kg  2.0 mg/kg  2.5 mg/kg          
Week 3-Challenge Doses 
9:00  5.0 mg/kg        5.0 mg/kg          
10:00  5.0 mg/kg        5.0 mg/kg          
11:00  5.0 mg/kg        5.0 mg/kg          
12:00  5.0 mg/kg        5.0 mg/kg          
13:00  5.0 mg/kg        5.0 mg/kg          
14:00  5.0 mg/kg        5.0 mg/kg          
The rats were initially divided into two groups, with one group receiving saline and the other group getting METH pre-treatment according to the schedule described above during 
the first and second weeks.  Challenge doses were given either on Monday or Thursday of the third week or both days.  The saline pre-treatment was followed by either saline on 
both challenge days (SSS), METH on the second challenge day (SSM) or METH on both challenge days (SMM).  The METH pre-treatment was followed by METH challenges on 
both days (MMM).  All animals were killed two weeks later. Long-Term Protective Effects of Methamphetamine Preconditioning  Current Neuropharmacology, 2011, Vol. 9, No. 1    37 
ultrasonicated in 0.01M perchloric acid, then centrifuged at 
20,000g for 15 min. Concentrations of norepinephrine (NE), 
DA, DOPAC, HVA, 5-HT, and 5-HIAA in brain tissue ex-
tracts of METH- and saline-treated rats were measured by 
HPLC with electrochemical detection as described earlier 
[22]. Concentrations of DA, DOPAC, HVA, 5-HT, and 5-
HIAA were calculated and expressed as pg/mg of tissue 
weight and shown as percentages of control concentrations. 
Breeze (Waters Corp), a software program, was used to cal-
culate peak height and to integrate known standards for the 
HPLC data. 
Statistical Analysis 
  Values, expressed as pg/mg wet tissue, for each mono-
amine or metabolite in each brain region were imported into 
StatView (SAS Institute) for statistical analysis. Statistical 
analysis was performed using analysis of variance (ANOVA) 
followed by Fisher’s protected least significant difference 
(PLSD) (StatView 4.02, SAS Institute, Cary, NC). Differ-
ences were considered significant at p < 0.05. 
RESULTS 
METH Caused Increases in Tympanic Temperature in 
the Rat 
  There were no significant differences in initial body tem-
perature between any of the groups prior to the first injec-
tion. After the first injection, all groups challenged with 
METH had significantly higher body temperatures than the 
group treated with saline. These increases in body tempera-
ture persisted throughout the time of observation, as shown 
in Fig. (1). 
METH Preconditioning Protects Against METH-Induced 
Monoamine Depletion 
Striatum 
  The effects of METH on DA and its metabolites, DO-
PAC and HVA, in the striatum are shown in Fig. (2). METH 
caused significant decreases in DA levels [F(4,26) = 7.860, p = 
0.003], see Fig. (2A). Post-hoc analyses revealed that the 
SSM group showed significant METH-induced decreases (-
49.96%), with the second METH challenge not causing any 
further DA depletion (-55.62%) in the SMM group. The 
METH-pretreated rats were protected against METH chal-
lenge-induced DA depletion in comparison to the SSM and 
SMM groups, as shown in Fig. (2A). METH also caused 
decreases in DOPAC levels in the striatum [F(4,26) = 5.360, p 
= 0.003], see Fig. (2B). The SSM group experienced signifi-
cant METH-induced decreases compared to the METH-
pretreated rats (-26.41%); the second METH challenge did 
not cause any further DOPAC depletion (-28.99%) in the 
SMM group. The METH–pretreated rats were protected 
against METH challenge-induced DOPAC depletion. HVA 
levels were not significantly affected after the drug challenge 
[F(4,26) = 0.051, p = 0.995] (data not shown). 
  The effects of METH on 5-HT and its metabolite, 5-
HIAA, are shown in Figs. (2C and 2D). METH caused   
decreases in 5-HT levels in the striatum [F(4,26) = 3.307,   
p = 0.035]. Post hoc analyses showed that the SSM group 
experienced significant METH-induced 5-HT decreases   
(-31.15%). A second METH challenge did not cause further 
5-HT depletion (-35.23%) in the SMM group. The METH-
pretreated rats were protected against METH challenge-
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). METH induced changes in tympanic temperatures in the rat. Temperatures were measured in all animals in the two treatment groups 
after injections of either METH (6 X 5 mg/kg, every hour) or saline challenges. Values are expressed as means ± SEM, N = 6-10 animals per 
group. Key to statistics: *** p < 0.001 versus SSS group; + p < 0.05 and ++ p < 0.01 versus SMM group. 
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induced 5-HT depletion in comparison to the SSM and SMM 
groups. 5-HIAA levels were significantly decreased (-38.47%) 
in the SMM group [F(4,26) = 2.205, p = 0.013], see Fig. (2D). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Effects of METH pretreatment and challenge on striatal 
DA (A), DOPAC (B), 5-HT (C), and 5-HIAA (D) levels. Values 
are expressed as percentages of the SSS group (mean ± SEM). N = 
5-8 animals per group. Key to statistics: *p < 0.05, ** p < 0.01, and 
*** p < 0.0001 versus SSS group; +p < 0.05 versus MMM. 
Cortex 
  The effects of METH on the 5-HT system in the cortex 
are shown in Figs. (3A and 3B). METH caused significant 
decreases in 5-HT levels in the cortex [F(5,31) = 6.231, p = 
0.0004]. The SSM group experienced significant METH-
induced decreases (-46.03%), but a second METH challenge 
did not cause any further 5-HT depletion (-52.01%) in the 
SMM group. The METH-pretreated rats were protected 
against the METH challenge-induced 5-HT depletion. The 
effects of METH on the 5-HT metabolite, 5-HIAA, are 
shown in Fig. (3B). The METH challenge induced signifi-
cant decreases in cortical 5-HIAA levels [F(5,32) = 3.893, p = 
0.007]. The SSM group showed significant METH- induced 
decreases (-27.69%), whereas a second METH challenge did 
not cause further 5-HIAA depletion in the cortex (-42.71%) 
(compare SSM to SMM group). The METH-treated rats 
were protected against METH challenge-induced 5-HIAA 
depletion (compare MMM to SSM and SMM groups). 
Hippocampus 
  The effects of METH on hippocampal 5-HT and 5-HIAA 
are presented in Figs. (3C and 3D). METH caused decreases 
in hippocampal 5-HT levels [F(4,26) = 3.067, p = 0.034]. The 
SSM group showed significant METH-induced decreases   
(-25.06%), whereas a second METH challenge did not cause 
any further 5-HT depletion in the SMM group (-36.78%). 
The METH-treated rats were protected against METH chal-
lenge-induced 5-HT depletion in comparison to the SSM   
and SMM groups, as shown in Fig. (3C). The SMM group 
experienced significant METH-induced 5-HIAA decreases   
(-42.56%) compared to SSS, see Fig. (3D). The METH-
treated rats were protected against METH challenge-induced 
5-HIAA depletion in comparison to the SSM and SMM 
groups.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Effects of METH pretreatment and challenge on levels of 
cortical 5-HT (A) and 5HIAA (B) and of hippocampal 5-HT (C) 
and 5HIAA (D) after METH pretreatment and challenges. Values 
are expressed as percentages of the SSS group. Data are means ± 
SEM, n= 5-8 animals per group. Key to statistics: *p < 0.05 and ** 
p < 0.01 versus SSS group; +p < 0.05 versus MMM. 
DISCUSSION 
  The main finding of the present paper is that METH pre-
conditioning can protect against the long-term biochemical 
effects of a toxic dose of the drug. The protective effects of 
METH pretreatment were observed in animals killed 14 days 
after the METH challenge. METH-pretreated animals also 
had significantly higher body temperatures compared to con-
trols. These data suggest that protection caused by METH-
preconditioning does not depend on changes in temperature. 
These results are consistent with data from previous studies 
that have used different pretreatment paradigms [17-19, 23-
25].  
  Neuroprotection reported in animals that underwent the 
process of METH preconditioning have included significant 
attenuation of METH-induced depletion of monoamines [17, 
19, 24] as well as METH-induced abnormalities in the activi-
ties of tyrosine hydroxylase (TH) and trypotophan hydroxy-
lase (TPH) [24]. METH pretreatment can also attenuate 
METH-induced striatal DAT [23, 25] and VMAT-2 reduc-
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tions [25]. Thus, when taken together, these observations 
suggest that repeated injections of low doses of METH 
might render the brain refractory to the toxic effects of binge 
injections of the drug, thus providing protection against toxic 
METH effects in various brain regions. 
  We found, in addition, that a second challenge with a 
toxic METH regimen did not cause further reduction in 
monoamine levels. This suggests that the first challenge 
might have triggered protective mechanisms in the brain. 
These results are consistent with those of Hanson et al. [27] 
who recently reported that subsequent challenges with toxic 
doses of METH did not cause further abnormalities in striatal 
DA levels, DAT function, and VMAT-2 function. Mecha-
nisms underlying this neuroprotection might include activa-
tion of antioxidant enzymes and chaperone proteins such as 
heat shock proteins [28]. The possibility that this pattern of 
METH might also interfere with the ability of mitochondria 
to generate toxic free radicals also needs to be considered 
[9]. More comprehensive studies are underway to test these 
ideas. 
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